The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C08 | Calcium channel blockers | |
| 3 | C08D | Selective calcium channel blockers with direct cardiac effects | |
| 4 | C08DB | Benzothiazepine derivatives | |
| 5 | C08DB01 | Diltiazem |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.24 g |
| Active Ingredient | Description | |
|---|---|---|
| Diltiazem |
Diltiazem is a calcium antagonist. It restricts the slow channel entry of calcium into the cell and so reduces the liberation of calcium from stores in the sarcoplasmic reticulum. This results in a reduction of the amount of available intracellular calcium reducing myocardial oxygen consumption. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ADIZEM-XL Prolonged release capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| CARDIZEM CD Extended-release capsule | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| TIAZAC Capsule, ectended release | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| TILDIEM Modified-release tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
